Enzymotec (ENZY) Misses Q2 EPS by 8c; Cuts FY14 Outlook

Enzymotec (NASDAQ: ENZY) reported Q2 EPS of $0.02, $0.08 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $11.5 million versus the consensus estimate of $14.88 million.

Enzymotec sees FY2014 EPS of $0.34-$0.43, versus the consensus of $0.82. Enzymotec sees FY2014 revenue of $62-70 million, versus the consensus of $78.4 million.

For earnings history and earnings-related data on Enzymotec (ENZY) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Kenon Holdings (KEN) halted, news pending
• Bio-key International, Inc. (BKYI) Tops Q2 EPS by 24c